glycogen

(redirected from glycogen storage disease)
Also found in: Dictionary, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
  • noun

Synonyms for glycogen

one form in which body fuel is stored

References in periodicals archive ?
Glycogen storage disease type II: acid [alpha]-glucosidase (acid maltase) deficiency.
A diagnostic protocol for adult-onset glycogen storage disease type II.
The researchers conservatively estimate that about one in 2,500 people in Nunavik may have glycogen storage disease type Ilia.
Glycogen storage disease type II: Acid alpha-glucosidase (acid maltase) deficiency.
A diagnosis of glycogen storage disease type 1a was made with increased amount of glycogen and decreased G6Pase activity in the liver biopsy specimens and/or mutation analysis in the G6Pase gene.
Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper.
Clinical and laboratory findings in four patients with the non-progressive hepatic form of type IV glycogen storage disease.
Association for Glycogen Storage Disease PO Box 896 Durant, IA 52747 (319) 785-6038 (voice/fax) 1,6,9,10
Glycogen Storage Disease has been divided into at least 10 different types based on the deficiency of a particular enzyme which controls blood sugar levels.
RARE Champion Award - Advocacy - Honoring Dylan Siegel, a 6-year-old 1st grader who wrote a book called "Chocolate Bar" to raise money towards a cure for his best friend's (Jonah Pournazarian) rare liver condition called Glycogen Storage Disease 1b, http://chocolatebarbook.
The mutations which occur in this gene have been associated with glycogen storage disease type III (GSD III, MIM#232400).
The patient's restrictive cardiomyopathy was suspected to be due to amyloidosis since there were no indications for endomyocardial fibrosis, sarcoidosis, hemochromatosis, Fabry or Gaucher disease, Hurler syndrome, or glycogen storage disease.
The authors postulate that adult polyglucosan body disease is one manifestation of glycogen storage disease type IV, the other clinical presentations being hepatic and neuromuscular forms.
The 12-year-old suffers from rare glycogen storage disease, which means her liver cannot release glucose to give her energy.
His translational research leads to the development of now standard therapies for two devastating inherited metabolic diseases: a simple and effective cornstarch therapy for severe hypoglycemia in glycogen storage diseases and an enzyme replacement therapy, the first ever treatment, for a debilitating, progressive and often fatal myopathy called Pompe disease.
Full browser ?